Geron Corporation (GERN)
NASDAQ · Healthcare
$1.440.00%
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $910.96M
- P/E ratio
- —
- EPS
- —
- Volume
- 5,150,611
- 52-week high
- —
- 52-week low
- —
- Open
- $1.44
- Day high
- $1.48
- Day low
- $1.41
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | — | -$83.5M | -$0.13 |
| 2024 | — | -$174.57M | -$0.27 |
| 2023 | $237K | -$184.13M | -$0.32 |
| 2022 | $596K | -$141.9M | -$0.37 |
| 2021 | $1.39M | -$116.11M | -$0.35 |
About Geron Corporation
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
- CEO
- Harout Semerjian
- Employees
- 258
- Country
- US
- IPO date
- Jul 31, 1996
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Geron Corporation's stock price today?
- GERN is trading at $1.44 as of Jul 20, 2026.
- What is Geron Corporation's market cap?
- Geron Corporation (GERN) has a market capitalization of $910.96M.
- Does Geron Corporation pay a dividend?
- Geron Corporation did not pay a dividend in its most recent reported fiscal year.
- What sector is Geron Corporation in?
- Geron Corporation operates in the Healthcare sector.